Delisting risk
Barinthus Biotherapeutics (ADR) (BRNS)
Develops immune-tolerance therapies for celiac disease while seeking partners for legacy viral-vector programs.
$0.7600
Pre-market−0.01 (−1.92%)
At close$0.7749(+1.29%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Insiders2 holders · as of Feb 11, 2025 | 9.85% | 4.03M ADS | |
| Strategic holders1 holder · as of Apr 13, 2026 | 6.69% | 2.73M ADS | |
| Otherremainder | 83.46% | 34.09M ADS |
40.85M ADS as of Sep 3, 2026 · holders as of their latest filing
Institutions13F
No 13F holders on record.
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Frank W. Cawood | 8.40% | 3.38M | 13G | Feb 11, 2025 ↗ |
| International Generosity Foundation Trust | 6.70% | 2.73M | 13D | Apr 13, 2026 ↗ |
Insider tradesForm 4
Latest trades
Nothing filed in the last 12 months.
CongressHouse and Senate disclosures
Not reported.